Preliminary application of I-125-nivolumab to detect PD-1 expression in colon cancer via SPECT
Preliminary application of I-125-nivolumab to detect PD-1 expression in colon cancer via SPECT
复制标题
I-125-nivolumab SPECT检测结肠癌PD-1表达的初步应用
DOI：
10.1007/s10967-018-6124-6
复制
发表时间：
2018
影响因子：
1.6
通讯作者：
Changjing Zuo
中科院分区：
文献类型：
--
作者：
Danni Li;Cheng Wang;Dakuan Zhang;Ye Peng;Shengnan Ren;Xiao Li;Changjing Zuo
精确检测PD-1/PD-L1生物标志物有助于预测相应免疫治疗的预后。125i标记的nivolumab靶向浸润肿瘤组织的活化免疫细胞，以评估PD-1免疫检查点的表达。SPECT图像显示125i - nivolumab优先靶向肿瘤周围的免疫细胞。这种放射性示踪剂可以动态定量地表征结直肠癌免疫检查点的体内表达，从而有可能对患者进行早期筛查，监测治疗效果，评估潜在的免疫毒性。
The precise detection of PD-1/PD-L1 biomarkers helps to predict the prognosis of corresponding immunotherapy.125I-labeled nivolumab targeting activated immune cells infiltrating the tumorous tissues was developed to evaluate the expression of PD-1 immune checkpoints. SPECT images indicated that125I–nivolumab preferentially targeted to tumor-surrounded immune cells. This radiotracer can dynamically and quantitatively characterize the in vivo expression of immune checkpoints for colorectal cancer, thereby potentially enabling the early screening of patients, monitoring the efficacy of treatment, and assessing potential immunotoxicity.